DEVELOPING REVOLUTIONARY REGULATORS OF THE COMPLEMENT SYSTEM

QUASAR Therapeutics develops novel regulators of the complement system to revolutionize the treatment of life-threatening diseases. Current inhibitors in the clinic are insufficient and patients still suffer from their symptoms despite complement inhibition. We solve this problem with our novel regulators based on human complement proteins. We have demonstrated outstanding data for our lead molecule and currently work on the in vivo Proof of Principle of our lead indication.

Incorporation planned for 2025.

www.linkedin.com/company/quasar-therapeutics


Vision of QUASAR Therapeutics:

"Since our participation in the Biotech Bootcamp, we have been part of BioM's impressive ecosystem and have been supported ever since. Today, we are very happy and grateful to have joined the MAxL Incubator, because this is the right place to realize our vision."


The management team of QUASAR Therapeutics:

  • Matteo Mohr, Co-Founder and CEO - LinkedIn profile

  • Dr. Arthur Dopler, Co-Founder and CSO - LinkedIn profile

  • Nadja Späth

  • Dr. Monika Hunjadi

  • Prof. Dr. Christoph Schmidt

  • Prof. Dr. Markus Huber-Lang (not pictured)

  •